Heparin sodium
Calciparine, Defencath, Embolex, Heparin (heparin sodium) is an oligosaccharide pharmaceutical. Heparin sodium was first approved as Calciparine on 1982-01-01. It is used to treat cerebral infarction, coronary thrombosis, myocardial infarction, postoperative complications, and pulmonary embolism amongst others in the USA. The pharmaceutical is active against antithrombin-III.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Heparin
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| defencath | New Drug Application | 2025-09-29 |
| heparin | unapproved drug other | 2012-08-09 |
| heparin sodium | unapproved drug other | 2014-12-24 |
| heparin sodium | ANDA | 2026-06-02 |
| heparin sodium and dextrose | New Drug Application | 2026-05-25 |
| heparin sodium and sodium chloride | New Drug Application | 2019-04-19 |
| heparin sodium in dextrose | New Drug Application | 2023-07-31 |
| heparin sodium in sodium chloride | New Drug Application | 2025-08-06 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
HEPARIN SODIUM / TAUROLIDINE, DEFENCATH, CORMEDIX | |||
| 2033-11-15 | GAIN | ||
| 2028-11-15 | NCE | ||
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AB: Heparin group antithrombotic drugs
— B01AB01: Heparin
— B01AB51: Heparin, combinations
— B01AC: Platelet aggregation inhibitors excl. heparin
— B01AC30: Platelet aggregation inhibitor combinations excl. heparin
C: Cardiovascular system drugs
— C05: Vasoprotectives
— C05B: Antivaricose therapy drugs
— C05BA: Heparins or heparinoids for topical use
— C05BA03: Heparin
— C05BA53: Heparin, combinations
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01X: Other ophthalmologicals in atc
— S01XA: Other ophthalmologicals in atc
— S01XA14: Heparin
Clinical
Clinical Trials
1757 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombosis | D013927 | — | — | 12 | 35 | 58 | 49 | 96 | 237 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 8 | 37 | 74 | 31 | 69 | 208 |
| Thromboembolism | D013923 | — | — | 8 | 37 | 74 | 36 | 63 | 207 |
| Venous thrombosis | D020246 | — | I82.40 | 7 | 28 | 47 | 40 | 61 | 174 |
| Covid-19 | D000086382 | — | U07.1 | 6 | 27 | 35 | 14 | 39 | 107 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | 9 | 10 | 33 | 25 | 31 | 103 |
| Embolism | D004617 | — | — | 8 | 8 | 24 | 18 | 21 | 74 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 4 | 17 | 23 | 25 | 68 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | 7 | 13 | 14 | 23 | 56 |
| Neoplasms | D009369 | — | C80 | 3 | 6 | 15 | 5 | 27 | 54 |
Show 188 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 18 | 3 | 1 | — | 5 | 25 |
| Septic shock | D012772 | — | A48.3 | 2 | 4 | 2 | — | 14 | 22 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 2 | 5 | — | 14 | 21 |
| Multiple myeloma | D009101 | — | C90.0 | 3 | 4 | 2 | — | 6 | 14 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | 2 | — | 11 | 13 |
| Replacement arthroplasty knee | D019645 | — | — | — | 5 | 3 | — | 1 | 9 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | 2 | 4 | 2 | — | 4 | 9 |
| Lymphoma | D008223 | — | C85.9 | 2 | 3 | 1 | — | 3 | 8 |
| Plasma cell neoplasms | D054219 | — | — | 3 | 2 | 1 | — | 3 | 8 |
| Coagulation protein disorders | D020147 | — | — | 1 | — | 2 | — | 5 | 8 |
Show 104 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cholangiocarcinoma | D018281 | — | C22.1 | 1 | 5 | — | — | 1 | 7 |
| Coronary stenosis | D023921 | EFO_1000882 | — | — | 1 | — | — | 4 | 5 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 3 | — | — | 2 | 5 |
| Congenital heart defects | D006330 | — | Q24.9 | 1 | 1 | — | — | 3 | 5 |
| Carotid artery diseases | D002340 | EFO_0003781 | — | — | 1 | — | — | 3 | 4 |
| Myeloid leukemia | D007951 | — | C92 | 3 | 1 | — | — | — | 4 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 2 | 1 | — | — | 2 | 4 |
| Systemic inflammatory response syndrome | D018746 | EFO_1001478 | R65.10 | — | 1 | — | — | 3 | 4 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 1 | 2 | — | — | 1 | 3 |
| B-cell lymphoma | D016393 | — | — | 2 | 2 | — | — | — | 3 |
Show 70 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Blood platelet disorders | D001791 | — | — | 1 | — | — | — | 3 | 4 |
| Blood pressure | D001794 | EFO_0004325 | — | 2 | — | — | — | 1 | 3 |
| Intracranial hypertension | D019586 | EFO_1000992 | — | 1 | — | — | — | 1 | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | 1 | 2 |
| Hodgkin disease | D006689 | — | C81 | 1 | — | — | — | 1 | 2 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | 1 | — | — | — | 1 | 2 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 1 | — | — | — | 1 | 2 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | 1 | 2 |
| Sensorineural hearing loss | D006319 | — | H90.5 | 1 | — | — | — | 1 | 2 |
| Nasopharyngeal carcinoma | D000077274 | — | — | 1 | — | — | — | — | 1 |
Show 23 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative complications | D011183 | — | — | — | — | — | — | 6 | 6 |
| Carotid stenosis | D016893 | — | — | — | — | — | — | 6 | 6 |
| Chest pain | D002637 | — | R07.9 | — | — | — | — | 5 | 5 |
| Pathologic constriction | D003251 | — | — | — | — | — | — | 5 | 5 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | — | — | 4 | 4 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | — | — | 4 | 4 |
| Post-acute covid-19 syndrome | D000094024 | — | — | — | — | — | — | 4 | 4 |
| Cytokine release syndrome | D000080424 | — | D89.83 | — | — | — | — | 3 | 3 |
| Blood coagulation | D001777 | GO_0007596 | — | — | — | — | — | 3 | 3 |
| Esophageal and gastric varices | D004932 | EFO_0009545 | I85 | — | — | — | — | 3 | 3 |
Show 237 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Heparin sodium |
| INN | heparin sodium |
| Description | Heparin, also known as unfractionated heparin (UFH), is a medication and naturally occurring glycosaminoglycan. Heparin is a blood anticoagulant that increases the activity of antithrombin. It is used in the treatment of heart attacks and unstable angina. It can be given intravenously or by injection under the skin. Its anticoagulant properties make it useful to prevent blood clotting in blood specimen test tubes and kidney dialysis machines.
|
| Classification | Oligosaccharide |
| Drug class | heparin derivatives and low molecular weight (or depolymerized) heparins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 9005-49-6 |
| RxCUI | 5224 |
| ChEMBL ID | CHEMBL1201657 |
| ChEBI ID | — |
| PubChem CID | 22833565 |
| DrugBank | DB01109 |
| UNII ID | ZZ45AB24CA (ChemIDplus, GSRS) |
Target
Agency Approved
SERPINC1
SERPINC1
Organism
Homo sapiens
Gene name
SERPINC1
Gene synonyms
AT3
NCBI Gene ID
Protein name
antithrombin-III
Protein synonyms
serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1, Serpin C1, serpin peptidase inhibitor clade C member 1, serpin peptidase inhibitor, clade C (antithrombin), member 1
Uniprot ID
Mouse ortholog
Serpinc1 (11905)
antithrombin-III (P32261)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21,057 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use